Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool April 8, 2005 Charly Travers	The FDA Hammers Pfizer Regulatory agency orders a billion dollar blockbuster off the market. Should investors care?
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool October 30, 2007 Charly Travers	Winners and Losers in Big Pharma Some drugmakers are hitting a slump, but not all of them. Which ones can still cure what ails your portfolio?
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool January 19, 2005 Stephen D. Simpson	Pfizer Doesn't Give Much Fizz The company reports mediocre earnings as investors remain nervous about the drug sector.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
The Motley Fool November 25, 2011 Dan Caplinger	Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
The Motley Fool November 9, 2006 Brian Lawler	The Best Blue Chip for 2007: GlaxoSmithKline Here's a blue-chip pharma stock for your portfolio.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool May 31, 2007 Ryan Fuhrmann	Dueling Fools: Eli Lilly Bull Rebuttal Investors need to keep looking for further proof that Lilly's valuation premium to its peers is fully warranted, but if current trends are any indication, its growth prognosis could lead the industry.
The Motley Fool October 11, 2004 Roger Nusbaum	Pfizer: Prognosis Critical This American icon seems destined to lag for the forseeable future.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool September 15, 2010 Brian Orelli	Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool June 14, 2007 Ryan Fuhrmann	Dueling Fools: GlaxoSmithKline Bear Glaxo is definitely a safe bet in the industry, and Avandia concerns have brought the share levels to even more reasonable levels. But investors can find the risk/reward trade-off even more compelling in other names.
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
The Motley Fool July 7, 2004 Charly Travers	Pfizer Wants to Be Your Pfriend It seems that the pharmaceutical is limiting its profits in certain markets on its own terms in the hopes that concessions will be sufficient to keep from being handcuffed by Congress.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool August 12, 2011 David Williamson	What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter?
The Motley Fool November 23, 2004 W.D Crotty	5 Drugs to Worry About? The recall of Merck's Vioxx raises concern among investors that there may be other pharmaceutical companies with potential legal exposure.
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool July 22, 2011 Matt Koppenheffer	Could Eli Lilly's Stock Double Your Money? With concerns swirling around the big pharma companies, could it be time to buy Eli Lilly?
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool June 8, 2011 Brian Orelli	Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming.